Recently, the well-known pharmaceutical industry media outlet Healthcare Executive and SynTao, a leading independent corporate social responsibility consulting firm in China, jointly released the "2023 China's Pharmaceutical Listed Companies for ESG Competitiveness" series of selection lists. For its excellent ESG management performance and outstanding industry competitiveness, Sino Biopharm was named to the "2023 China's Top 20 Pharmaceutical Listed Companies for ESG Competitiveness" list for the second consecutive year.

This year's list selection is based on core dimensions such as "ESG Information Transparency" and "ESG Management Performance", aiming to select representative pharmaceutical listed companies in terms of ESG management practices, and to provide a benchmark for the transformation and upgrading of China's pharmaceutical industry and the creation of sustainable competitiveness.

As a leading innovation and R&D-driven pharmaceutical group in China, Sino Biopharm has always practiced the concept of sustainability. Based on a top-down ESG governance structure, the Group continues to promote the comprehensive implementation of the "CARE"-centric ESG governance strategy, fostering the organic integration of ESG management with the Group's overall development strategy, and providing strong support for the sustainable development of the company, employees, society, and the environment.

Being selected again for the "2023 China's Top 20 Pharmaceutical Listed Companies for ESG Competitiveness" list represents the industry's affirmation of Sino Biopharm's comprehensive ESG competitiveness. This year, with its continuous investment and outstanding performance in the ESG field, Sino Biopharm has not only been included in this list but has also received widespread recognition. Recently, in the latest 2023 ESG rating results released by the international authoritative index agency MSCI (Morgan Stanley Capital International), Sino Biopharm received an A rating, achieving a rating upgrade for the third consecutive year. In the future, Sino Biopharm will, through high-quality ESG management, earnestly practice the Group's mission of "improving the quality and protecting the dignity of human life", seek health and well-being for more patients, and create long-term value for itself and partners from all sectors.